Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the ultrashort course subcutaneous allergy immunotherapy (AIT), continues to gain market share, despite its availability in the EU only on a “named-patient” basis. Several products are in clinical development, with the aim of moving the platform to full registration under the new regulatory frameworks in both the EU and the US. Management has the plan and resources to achieve the ultimate goal: to be the first to launch a fully-regulated subcutaneous immunotherapy product in the US market.
26 Sep 2019
Continuing to gain market share
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Continuing to gain market share
Allergy Therapeutics plc (AGY:LON) | 2.8 0 1.8% | Mkt Cap: 135.8m
- Published:
26 Sep 2019 -
Author:
Martin Hall -
Pages:
16
Allergy Therapeutics (AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the ultrashort course subcutaneous allergy immunotherapy (AIT), continues to gain market share, despite its availability in the EU only on a “named-patient” basis. Several products are in clinical development, with the aim of moving the platform to full registration under the new regulatory frameworks in both the EU and the US. Management has the plan and resources to achieve the ultimate goal: to be the first to launch a fully-regulated subcutaneous immunotherapy product in the US market.